#POLB Poolbeg Pharma PLC – POLB 001 LPS Trial Data to be Presented at IUIS
16 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that an abstract highlighting the potential of POLB 001 as a groundbreaking therapy has been accepted for presentation at the 18th International Congress of […]
#TEK Capital investee company #BELL Belluscura PLC – Orders for over 6,500 DISCOV-R™ received
LONDON, U.K. AND PLANO, TX, U.S. (16 August 2023). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that it has received purchase orders for over 6,500 of its next-generation DISCOV-R portable oxygen concentrator. This represents approximately $15 million of potential revenue to the Company, with initial production of the DISCOV-R expected to […]
#TEK Tekcapital PLC investee co #BELL Belluscura PLC – appoints Senior VP of Global Sales
Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that Robert (“Bob”) Fary has joined the Company as Senior Vice President of Global Sales. Bob has thirty-years of experience in the respiratory industry where he has held leadership roles at major oxygen concentrator manufacturers and […]
#TEK TekCapital Plc investee co. #BELL Belluscura Plc – Year-end Trading Update
LONDON, U.K. AND PLANO, TX, U.S. (13 January 2023) Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen concentrator (“POC”) technology, provides a trading update for the year ended 31 December 2022. The Group is pleased to announce that it has made considerable progress this year. Since the launch of […]
#POLB Poolbeg Pharma PLC – Poolbeg identifies novel RSV drug candidates
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading infectious disease focused biopharmaceutical company, announces that it has successfully identified potential new drug candidates from its Respiratory Syncytial Virus (‘RSV’) artificial intelligence (‘AI’) Programme with OneThree Biotech, Inc. Since initiating the collaboration in February 2022, Poolbeg’s scientific team has worked closely with OneThree to […]
#HVO Hvivo – Imutex Phase I data published
hVIVO plc (AIM & Euronext: HVO) (formerly Open Orphan plc), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces publication of previously reported positive data from a first-in-human Phase I clinical study evaluating the safety and immunogenicity of AGS-v PLUS. […]
#POLB Poolbeg Pharma PLC – Metabolic diseases oral delivery licence signed
Clinical trial to demonstrate technology can safely deliver GLP-1 to commence in H1 2023 Prof Brendan Buckley joins Poolbeg’s Scientific Advisory Board to guide clinical development of technology Licence expands Poolbeg’s existing exclusive licence to AnaBio’s oral vaccine delivery technology Investor Meet Company presentation on 14 December 2022 at 5:30pm Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, […]
#TEK Tek Capital PLC – Investee Company #BELL Belluscura PLC
Belluscura, a leading medical device developer focused on lightweight and portable oxygen enrichment technology, is pleased to announce it has entered into its first international distribution agreement outside of the US, with MedHealth Supplies of South Africa (“MedHealth”). Following the distribution agreement, MedHealth has placed orders for both 2022 and 2023, with deliveries to commence […]
#POLB Poolbeg Pharma Plc- Capital Markets Day
17 November 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that it will be holding a Capital Markets Day for analysts and institutional investors on Wednesday 30 November between 10am – 12:45pm. The event, which […]
#HVO hVIVO plc- Share Price
hVIVO plc (AIM: HVO) (formerly Open Orphan plc), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, saw the share price rise which was then picked up in the Daily Mail Stock Watch this morning For further information please contact: […]